Inclusion Criteria:

• Histologically confirmed malignancy (excluding central nervous system malignancy)
• Not a candidate for, or refuses, anti-neoplastic therapy.
• Between the ages of 18 and 80.
• Symptoms of advanced cancer (loss of appetite, fatigue, weakness, malaise) that are not attributed to anemia, concomitant illnesses, or obstruction or loss of organ function.
• Karnofsky performance status of >40% to < 80%.
• Normal cognition, interpreted as a Mini-Mental State Examination score of at least 20.
• Life expectancy of >4 months.
• Decrease in weight of at least 5% over the preceding 6 months, with no weight gain over the most recent 30 days
• Pretreatment laboratory data within 7 days of enrollment (if screening labs are done within 3 days of Day 1, they need not be repeated on Day 1).
• Hemoglobin >8.5 g/dL on no, or on stable doses (hematocrit stable within 1 gram and dose stable for one month) of Epogen or similar medication.
• Absolute neutrophil count (ANC) >1,500/mm3.
• Platelets >50,000/mm3.
• Total bilirubin >1.5 the upper limit of normal (ULN).
• ALT and AST >2.5 times the ULN, or, if the patient has liver metastases, >= 5 times the ULN.
• Creatinine >1.5 mg/dL.
• Fasting blood sugar <= 1.2 x ULN
• Normal T3, T4, thyroid-stimulating hormone (TSH)
• Voluntary written informed consent before performance of any study-related procedure that is not part of normal medical care.
• Ability to self-administer subcutaneous medication, or to have an assistant who can administer the study medication according to the protocol.
• Female patient is post-menopausal, surgically sterilized, or willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.
• Male patient agrees to use an acceptable barrier method for contraception during the study.
• If on an antidepressant, the dose must have been stabilized for at least 60 days

Exclusion Criteria:

• Received chemotherapy, immunotherapy, radiation therapy or experimental therapy within three weeks.
• Diabetes requiring insulin or oral hypoglycemic agents.
• Mechanical reason for being unable to eat, or is reasonably expected to develop an obstruction during the next eight weeks
• Myocardial infarction within six months of enrollment.
• Uncontrolled brain metastases or central nervous system disease.
• Major surgery within four weeks of enrollment.
• Severe allergies to milk or milk products.
• Uncontrolled intercurrent illness or major organ failure, including, but not limited to, ongoing or active infection; pulmonary, renal, or hepatic failure; adrenal insufficiency; symptomatic congestive heart failure; unstable angina pectoris; or cardiac arrhythmia.
• Another serious medical or psychiatric illness that could, in the Investigator’s opinion, potentially interfere with the completion of treatment or clinical assessments according to this protocol.
• Female patient is pregnant or breast-feeding.